This clinical review highlights the identification of intermediate-risk pulmonary embolism patients and discusses indications for reperfusion therapy and NOAC use.
Answers are grounded in this paper and cite their sources.
Risk stratification informs PE treatment choices in stable patients; leaves open optimal strategies for intermediate-risk cases.
Current guidelines on the treatment of acute pulmonary embolism (PE) recommend stratification of hemodynamically stable patients in 'low risk' and 'intermediate risk'. Validated risk scores, cardiac biomarkers, and imaging of the right ventricle all help in distinguishing both patient categories. The relevance of this risk stratification lies in the determination of the most optimal treatment for the individual patient. In this clinical review, we will discuss how patients with 'intermediate-risk' PE can be identified as well as recent advances in their therapeutic management. Based on a clinical case, we will highlight the indications for reperfusion therapy and the current experience with non-vitamin K-dependent oral anticoagulant (NOACs) in this specific patient's category.
No takes yet. Share an insight, caveat, or question.
Klok et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: